These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30909984)

  • 21. Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses.
    Villareal VA; Rodgers MA; Costello DA; Yang PL
    Antiviral Res; 2015 Dec; 124():110-21. PubMed ID: 26526588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy.
    Li S; Yu X; Guo Y; Kong L
    Cell Microbiol; 2012 Jul; 14(7):994-1002. PubMed ID: 22329740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication.
    Magri A; Ozerov AA; Tunitskaya VL; Valuev-Elliston VT; Wahid A; Pirisi M; Simmonds P; Ivanov AV; Novikov MS; Patel AH
    Sci Rep; 2016 Jul; 6():29487. PubMed ID: 27406141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C: An unsuspected drug target.
    Murray CL; Rice CM
    Nature; 2010 May; 465(7294):42-4. PubMed ID: 20445618
    [No Abstract]   [Full Text] [Related]  

  • 25. Form confers function: Case of the 3'X region of the hepatitis C virus genome.
    Dutkiewicz M; Ciesiołka J
    World J Gastroenterol; 2018 Aug; 24(30):3374-3383. PubMed ID: 30122877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation.
    Wohl BM; Smith AA; Jensen BE; Zelikin AN
    J Control Release; 2014 Dec; 196():197-207. PubMed ID: 25451544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
    Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
    Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical relevance of HCV antiviral drug resistance.
    Welsch C; Zeuzem S
    Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Courtney-Smith M; Brancale A
    Eur J Med Chem; 2017 Jan; 125():1115-1131. PubMed ID: 27810598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus.
    Wei B; Kang J; Kibukawa M; Chen L; Qiu P; Lahser F; Marton M; Levitan D
    J Mol Diagn; 2016 Sep; 18(5):643-656. PubMed ID: 27393904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus: prospects for future therapies.
    Wilkinson T
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular biology of hepatitis C infection.
    Drazan KE
    Liver Transpl; 2000 Jul; 6(4):396-406. PubMed ID: 10915159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral hepatitis at a crossroad.
    Lok AS; Pawlotsky JM
    Gastroenterology; 2012 May; 142(6):1261-3. PubMed ID: 22537431
    [No Abstract]   [Full Text] [Related]  

  • 37. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.
    Kim SS; Peng LF; Lin W; Choe WH; Sakamoto N; Kato N; Ikeda M; Schreiber SL; Chung RT
    Gastroenterology; 2007 Jan; 132(1):311-20. PubMed ID: 17241881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
    Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
    Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-hepatitis C virus RdRp activity and replication of novel anilinobenzothiazole derivatives.
    Peng HK; Chen WC; Lin YT; Tseng CK; Yang SY; Tzeng CC; Lee JC; Yang SC
    Antiviral Res; 2013 Oct; 100(1):269-75. PubMed ID: 23994188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The molecular biology of hepatitis C virus].
    Koutsoudakis G; Forns X; Pérez-Del-Pulgar S
    Gastroenterol Hepatol; 2013 Apr; 36(4):280-93. PubMed ID: 23490024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.